Traws Pharma Inc - Company Profile
Powered by 
All the sales intelligence you need on Traws Pharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Traws Pharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Traws Pharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Traws Pharma Inc (Traws Pharma), formerly Onconova Therapeutics Inc, develops novel therapies to target critical threats to human health in respiratory viral diseases. The company is advancing investigational antiviral agents with potent activity against difficult-to-treat or resistant virus strains.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Traws Pharma's R&D arm focuses on rigosertib, narazaciclib, tivoxavir marboxil, and ratutrelvir. The company is advancing novel investigational antiviral agents with potent activity against difficult-to-treat or resistant virus strains that pose threats to human health. The product candidates are designed to be safe with simple dosing regimens, and the company employs accelerated clinical trial strategies to benefit patients who are especially vulnerable. Traws Pharma Inc is advancing two novel investigational oral small molecule antivirals targeting COVID-19/Long COVID and bird flu and seasonal influenza. Ratutrelvir is being developed as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease), while Tivoxavir marboxil is being developed as a single-dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). The R&D unit of Traws Pharma is responsible for developing novel therapies to target critical threats to human health in respiratory viral diseases. The unit is focused on advancing investigational antiviral agents and managing the company's clinical-stage product candidates. In FY2025, the company spent US$12.1 million on its R&D activities, which declined 5.5% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer